Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 69,100 shares, a decrease of 31.4% from the February 28th total of 100,700 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 214,100 shares, the days-to-cover ratio is currently 0.3 days.

Soligenix Trading Down 2.6 %

NASDAQ SNGX traded down $0.06 during trading on Friday, hitting $2.21. 61,177 shares of the company traded hands, compared to its average volume of 787,954. The company has a market capitalization of $5.55 million, a P/E ratio of -0.29 and a beta of 2.03. The business has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $3.06. Soligenix has a 12 month low of $1.83 and a 12 month high of $14.92.

Soligenix (NASDAQ:SNGX) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.20 million. During the same quarter last year, the firm posted ($12.66) earnings per share. Equities research analysts predict that Soligenix will post -4.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC grew its holdings in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,094 shares of the biopharmaceutical company’s stock after purchasing an additional 7,729 shares during the quarter. Geode Capital Management LLC owned about 1.04% of Soligenix worth $71,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.